Hyderabad, Nov 14 (IANS) Pharma major Dr Reddy's Laboratories Ltd on Tuesday launched Clofarabine injection, usually prescribed to treat a type of cancer of the white blood cells, in the US market.
Approved by the US Food and Drug Administration (USFDA), it is a therapeutic equivalent generic version of Clolar (clofarabine) injection.
The Clolar brand and generic had US sales of approximately $53 million MAT (Moving Annual Total) for the 12 months ended in September 2017, according to IMS Health, which provides information services for the healthcare industry.
Clofarabine injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL), the Hyderabad-based firm said in a statement.
Clolar is a registered trademark of Genzyme Corporation.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
About VDC
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.